Keros Therapeutics Begins Phase 2 Trial for Muscular Dystrophy Treatment

Keros Therapeutics, Inc. announced that the first patient has received their initial dose in a Phase 2 clinical trial. This trial is designed to assess the safety and efficacy of rinvatercept in individuals diagnosed with Duchenne muscular dystrophy (DMD).

DMD is a rare, progressive genetic disorder characterized by muscle degeneration and weakness, primarily affecting males. Currently, there is no cure for DMD, and treatments focus on managing symptoms and maintaining mobility.

Rinvatercept is an investigational therapeutic candidate developed to potentially improve muscle growth and repair mechanisms. This Phase 2 study aims to gather further data on rinvatercept's potential benefit for DMD patients. The study's outcomes will guide decisions regarding further clinical development.

Keros Therapeutics is a biopharmaceutical company focused on developing therapies for patients with severe unmet medical needs. The company's pipeline targets rare diseases, with the goal of delivering transformative treatments.